000156966 001__ 156966
000156966 005__ 20240229123124.0
000156966 0247_ $$2doi$$a10.1158/1055-9965.EPI-20-0184
000156966 0247_ $$2pmid$$apmid:32467345
000156966 0247_ $$2ISSN$$a1055-9965
000156966 0247_ $$2ISSN$$a1538-7755
000156966 0247_ $$2altmetric$$aaltmetric:83206583
000156966 037__ $$aDKFZ-2020-01271
000156966 041__ $$aeng
000156966 082__ $$a610
000156966 1001_ $$00000-0001-6224-1764$$aLujan-Barroso, Leila$$b0
000156966 245__ $$aMenstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort.
000156966 260__ $$aPhiladelphia, Pa.$$bAACR$$c2020
000156966 3367_ $$2DRIVER$$aarticle
000156966 3367_ $$2DataCite$$aOutput Types/Journal article
000156966 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1597321620_21565
000156966 3367_ $$2BibTeX$$aARTICLE
000156966 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156966 3367_ $$00$$2EndNote$$aJournal Article
000156966 500__ $$aVolume 29, Issue 8, 1 August 2020, Pages 1654-1664
000156966 520__ $$aUrothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk.We used an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models.During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR≥5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscle-invasive urothelial carcinoma risk was observed.Our results support that increasing the number of FTP may reduce urothelial carcinoma risk.More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.
000156966 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000156966 588__ $$aDataset connected to CrossRef, PubMed,
000156966 7001_ $$aBotteri, Edoardo$$b1
000156966 7001_ $$aCaini, Saverio$$b2
000156966 7001_ $$00000-0002-4121-3753$$aLjungberg, Börje$$b3
000156966 7001_ $$00000-0003-3071-1658$$aRoswall, Nina$$b4
000156966 7001_ $$00000-0003-4385-2097$$aTjønneland, Anne$$b5
000156966 7001_ $$aBueno-de-Mesquita, Bas$$b6
000156966 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b7
000156966 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b8
000156966 7001_ $$00000-0002-2368-1326$$aKiemeney, Lambertus A$$b9
000156966 7001_ $$00000-0001-8193-0370$$aLiedberg, Fredrik$$b10
000156966 7001_ $$aStocks, Tanja$$b11
000156966 7001_ $$aGunter, Marc J$$b12
000156966 7001_ $$aMurphy, Neil$$b13
000156966 7001_ $$aCervenka, Iris$$b14
000156966 7001_ $$00000-0001-8380-3439$$aFournier, Agnès$$b15
000156966 7001_ $$00000-0002-4557-3772$$aKvaskoff, Marina$$b16
000156966 7001_ $$aHäggström, Christel$$b17
000156966 7001_ $$aOvervad, Kim$$b18
000156966 7001_ $$aLund, Eiliv$$b19
000156966 7001_ $$00000-0002-1318-3972$$aWaaseth, Marit$$b20
000156966 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b21$$udkfz
000156966 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b22$$udkfz
000156966 7001_ $$aMenéndez, Virginia$$b23
000156966 7001_ $$00000-0003-4817-0757$$aSánchez, Maria-Jose$$b24
000156966 7001_ $$aSantiuste, Carmen$$b25
000156966 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, Aurora$$b26
000156966 7001_ $$00000-0002-6236-6804$$aZamora-Ros, Raul$$b27
000156966 7001_ $$00000-0002-0893-2377$$aCross, Amanda J$$b28
000156966 7001_ $$aTrichopoulou, Antonia$$b29
000156966 7001_ $$00000-0002-3275-2026$$aKarakatsani, Anna$$b30
000156966 7001_ $$aPeppa, Eleni$$b31
000156966 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b32
000156966 7001_ $$aKrogh, Vittorio$$b33
000156966 7001_ $$aSciannameo, Veronica$$b34
000156966 7001_ $$aMattiello, Amalia$$b35
000156966 7001_ $$aPanico, Salvatore$$b36
000156966 7001_ $$avan Gils, Carla H$$b37
000156966 7001_ $$00000-0002-2360-913X$$aOnland-Moret, N Charlotte$$b38
000156966 7001_ $$00000-0001-6750-1270$$aBarricarte, Aurelio$$b39
000156966 7001_ $$aAmiano, Pilar$$b40
000156966 7001_ $$aKhaw, Kay-Tee$$b41
000156966 7001_ $$aBoeing, Heiner$$b42
000156966 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b43
000156966 7001_ $$00000-0001-5256-0163$$aDuell, Eric J$$b44
000156966 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-20-0184$$gp. cebp;1055-9965.EPI-20-0184v2$$n8$$p1654-1664$$tCancer epidemiology, biomarkers & prevention$$v29$$x1538-7755$$y2020
000156966 909CO $$ooai:inrepo02.dkfz.de:156966$$pVDB
000156966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000156966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000156966 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000156966 9141_ $$y2020
000156966 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-17
000156966 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000156966 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000156966 980__ $$ajournal
000156966 980__ $$aVDB
000156966 980__ $$aI:(DE-He78)C020-20160331
000156966 980__ $$aUNRESTRICTED